Stopped: Study terminated due to meeting interim analysis futility endpoint. No difference was found between two treatment arms at interim analysis of primary outcome.
This phase II/III trial studies the best approach in improving quality of life and survival after a donor stem cell transplant in older, weak, or frail patients with blood diseases. Patients who have undergone a transplant often experience increases in disease and death. One approach, supportive and palliative care (SPC), focuses on relieving symptoms of stress from serious illness and care through physical, cultural, psychological, social, spiritual, and ethical aspects. While a second approach, clinical management of comorbidities (CMC) focuses on managing multiple diseases, other than cancer, such as heart or lung diseases through physical exercise, strength training, stress reduction, medication management, dietary recommendations, and education. Giving SPC, CMC, or a combination of both may work better in improving quality of life and survival after a donor stem cell transplant compared to standard of care in patients with blood diseases.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Improvement in health-related quality of life (HRQOL) (Phase II)
Timeframe: First 90 days after HCT
Survival after hematopoietic cell transplantation (HCT) (Phase III)
Timeframe: At 1 year after HCT
Change in HRQOL (Phase III)
Timeframe: Baseline to 90 days post-HCT